Researchers evaluated the efficacy and safety of guselkumab in patients with active psoriatic arthritis who were biologic-naive or treated with prior tumor necrosis factor inhibitors.
Investigators analyzed the prescribing practices for patients with psoriatic arthritis at an urban rheumatology office, with an emphasis on biologic prescribing.
AbbVie announced positive topline data from the phase 3 SELECT-PsA 2 trial of upadacitinib (Rinvoq) in patients with moderately to severely active psoriatic arthritis (PsA) who have had an inadequate response to ≥1 biologic disease modifying anti-rheumatic drugs (bDMARDs).
Researchers evaluated the effect of filgotinib vs placebo on the health-related quality of life in patients with psoriatic arthritis from the EQUATOR study.
Certolizumab pegol (CZP) may be safe and effective in the long-term treatment of psoriatic arthritis (PsA), according to a post hoc analysis presented at the 28th European Academy of Dermatology and Venereology Congress, held October 9 to 13, 2019, in Madrid, Spain. Researchers presented 4-year data from the RAPID-PsA trial (ClinicalTrials.gov Identifier: NCT01087788) that evaluated…
Researchers compared the efficacy and safety of ixekizumab with adalimumab in patients with both active psoriatic arthritis and joint and skin disease and with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs.
Researchers investigated the protein expression of interleukin (IL)-41 in the synovial tissue of patients with psoriatic arthritis, rheumatoid arthritis, and osteoarthritis and evaluated the production of IL-41 from the enthesis.
Researchers conducted a comparison study of outcomes in patients with psoriatic arthritis treated with secukinumab, apremilast, and other biologic medications.
This study was conducted to describe patterns of first and subsequent TNFi use and response to long-term TNFi therapy in patients with PsA.
Guselkumab (Tremfya) is already approved for moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
